2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2207 Heartbites: Cardiovascular toxicities in patients with hematologic malignancies managed with bispecific T-cell engagers

Grace M Ferri, MD, Allison Holzman2, Rutvij Merchant3, Elisa Bello4, Jordan Strom5, Michael Leukam, MD, MS6
1 Beth Israel Deaconess Medical Center, Boston, United States
2 Beth Israel Deaconess Medical Center, Boston, United States
3 Beth Israel Deaconess Medical Center, Boston, United States
4 Beth Israel Deaconess Medical Center, Boston, United States
5 Beth Israel Deaconess Medical Center, Boston, United States
6 Beth Israel Deaconess Medical Center, Boston, United States

Introduction: Bispecific T-cell engagers (BiTEs) have transformed the treatment of hematologic malignancies. Although emerging data suggest cardiovascular risk is not prohibitive, tools for clinician risk stratification are lacking. We aimed to characterize BiTE-associated cardiovascular events (CVAEs), assess changes in transthoracic echocardiograms (TTEs) before and after BiTE exposure, and derive a baseline cardiovascular (CV) risk score to identify patients at increased risk of CVAEs in a real-world cohort. 

Methods: We conducted a single-center retrospective chart review of adults initiating BiTE therapy at Beth Israel Deaconess Medical Center from 2016-2026. Clinical data and TTEs were obtained via structured queries and manual extraction. The primary endpoint was any new CVAE from first BiTE dose through 180 days after last dose, defined as arrhythmia, heart failure (HF), myocardial infarction or other acute coronary syndrome, thromboembolic or cerebrovascular event, clinically significant pericardial effusion, or cardiovascular death adjudicated by at least 1 unblinded physician reviewer. Secondary endpoints included longitudinal changes in TTE parameters within 180 days of BiTE administration.  

Pre-treatment clinical comorbidities associated with primary outcomes in univariate analysis were considered for inclusion in a multivariable risk score. We compared CVAE incidence across score strata and fit logistic regression models including the score as a continuous predictor. Discrimination of the score was assessed by area under the receiver operating characteristic curve (AUC) with internal validation by bootstrap resampling. 

Results: Within our cohort, median age at first BiTE infusion was 69 years (IQR 59-76) and 41.9% of patients were female. BiTEs studied included blinatumomab in 45 patients (30.4%), teclistamab in 32 (21.6%), glofitamab in 24 (16.2%), epcoritamab in 27 (18.2%), elranatamab in 15 (10.1%), talquetamab in 4 (2.7%), and mosunetuzumab in 1 (0.7%). Baseline CV comorbidities included: hypertension in 92 patients (62.2%), hyperlipidemia in 65 (43.9%), coronary artery disease (CAD) in 33 (22.3%), atrial fibrillation (AF) in 21 (14.2%), and HF in 20 (13.5%). Prior anthracycline exposure occurred in 45 patients (30.4%). 

Among 159 evaluable BiTE courses, 84/159 (52.8%) were complicated by ≥1 primary CVAE within 180 days. CVAE risk by hematologic diagnosis was 55.6% (35/63) for multiple myeloma, 54.5% (24/44) for diffuse large B-cell lymphoma, 36.4% (4/11) for follicular lymphoma, and 51.2% (21/41) for acute lymphoblastic leukemia (p=0.70). Patients with combined CVAEs (arrhythmia and HF) had the highest burden of baseline HF (32.4% vs. 14.2%, p=0.018) and AF (47.1% vs. 12.5%, p<0.001) compared to those with only arrhythmia or HF. Neither CRS nor ICANS grade was significantly associated with CVAEs (p>0.6). 

Among 26 patients with paired TTEs available, reported left ventricular ejection fraction (LVEF, combining biplane, 3D, visual estimates) remained stable (61.8±10.2% at baseline vs. 61.5±5.7% on-treatment; mean ΔLVEF -0.3±11.5%, p=0.89).  

Using a 3-point baseline CV risk score consisting of 1 point each for pre-existing CAD, AF, and HF, 102 courses (64.2%) had score 0; 28 (17.6%) had score 1; 25 (15.7%) had score 2; and 4 (2.5%) had score 3. Incidence of primary CVAEs increased across score strata (0 points: 44.1%; 1 point: 78.6%; 2 points: 52.0%; 3 points: 100%). In logistic regression, each 1-point increase in the score was associated with 1.58-fold higher odds of CVAEs (OR 1.58, 95% CI 1.07-2.38; p=0.024); this association remained significant after adjusting for age and sex (aOR 1.55, 95% CI 1.02-2.42; p=0.047). A model using only the 3-point score demonstrated an AUC of 0.60 (95% CI 0.53-0.68); in bootstrap internal validation, optimism-corrected AUC was similar (≈0.59). In exploratory analyses, no significant interaction between risk score and prior anthracycline exposure (interaction p=0.79) was found. 

Conclusion: Within this single-center cohort, more than half of patients experienced at least 1 new CVAE in the 180 days following BiTE treatment. We derived a 3-point baseline risk score demonstrating a gradient in CVAE risk that may help identify high-risk BiTE candidates. These findings support structured baseline CV risk assessment, cardio-oncology surveillance of active patients, and future efforts to externally validate and refine this score using multicenter cohorts. 

Grace M Ferri, MD: No relevant conflicts of interest to declare.